Alphamab Oncology Strikes Licensing Deal with CSPC Pharma for HER2 Targeted ADC in China
Alphamab Oncology (HKG: 9966), a biopharmaceutical company based in China, has entered into a licensing...
Sichuan Biokin’s Partner Bristol-Myers Squibb Gets FDA Nod for Bispecific ADC Study
Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a Chinese biopharmaceutical company, has announced that its...
J&J’s Carvykti Shows 45% Reduced Risk of Death in Multiple Myeloma Patients, Landmark Trial Data Reveals
Johnson & Johnson (J&J, NYSE: JNJ), a U.S.-based healthcare conglomerate, has released new clinical trial...
Yabao Pharmaceutical’s SY-009 Receives NMPA Approval for Phase II Clinical Trial in Constipation
Yabao Pharmaceutical Group Co., Ltd (SHA: 600351), a Chinese pharmaceutical company, has announced that SY-009...
Jiangsu Hengrui Pharmaceuticals Gets NMPA Green Light for Clinical Trial of TSLP-Targeted Asthma Treatment
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has...
Bayer AG Launches New Life Sciences Incubator in Shanghai to Boost Biotech Ecosystem
Bayer AG (ETR: BAYN, FRA: BAYN, OTCMKTS: BAYRY), a leading German life sciences company, announced...
Huadong Medicine Gets NMPA Green Light for Clinical Trials of Roflumilast Cream
Huadong Medicine Co., Ltd (SHE: 000963), a Chinese pharmaceutical company, has announced that it has...
LenoMed Medical’s Touch-Insulin Pump Receives NMPA Approval, Aids China’s Diabetes Management
Shanghai-based LenoMed Medical, a medical device platform company backed by Legend Capital and Legend Star,...
Mindray Bio-Medical Partners with Nanjing Drum Tower Hospital to Boost Clinical Research
Shenzhen Mindray Bio-Medical Electronics Co., Ltd (SHE: 300760), a leading medical equipment provider, has entered...
Qilu Pharmaceutical’s QL1706 Receives NMPA Conditional Approval for Cervical Cancer Treatment
Qilu Pharmaceutical, a Chinese pharmaceutical company, has announced that its combination drug QL1706, comprising iparomlimab...
Study Predicts 2025 Medicare Part D Negotiation Candidates, With Novo Nordisk’s Semaglutide Leading the List
Researchers in the U.S. have compiled a list of drugs that are anticipated to be...
Dupixent Secures Back-to-Back COPD Approvals from US FDA and China NMPA
Regeneron (NASDAQ: REGN), a leading biopharmaceutical company based in the U.S., in collaboration with its...
AbbVie Submits First BLA for c-Met Targeting ADC Telisotuzumab Vedotin to FDA
AbbVie Inc. (NYSE: ABBV), a leading pharmaceutical company in the U.S., has announced the filing...
Whittilong Pharma Secures Over RMB 100 Million in Series B Financing for Modified Drug Development
Whittilong Pharma, a Shanghai-based modified drug development company backed by Shanghai Healthcare Capital (SHC), has...
HOYA Surgical Optics Expands in China with New Artificial Intraocular Lens Facility
HOYA Surgical Optics has established its presence in the Suzhou High-Tech Zone of Jiangsu province,...
Shanghai Pharmaceuticals Partners with SIBPT to Boost Biopharmaceutical R&D and Translation
Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607) has entered into a partnership with the Shanghai...
Shanghai Fosun Pharmaceutical Gets NMPA Clinical Clearance for Lymphoma Drug XS-04
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a prominent pharmaceutical company based...
Shanghai Fosun Pharmaceutical’s SBK010 Stroke Treatment Accepted for NMPA Review
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a leading pharmaceutical company based...
3D Medicines’ H1’24 Financials Reflect Increased Comprehensive Loss Amid Revenue Decline
3D Medicines (HKG: 1244), a China-based oncology specialist, has released its financial report for the...
China Sets New Management Measures for Investigator-Initiated Trials in Medical Institutions
The National Health Commission (NHC), National Administration of Traditional Chinese Medicine, and National Disease Control...